Carbamylated low-density lipoprotein induces endothelial dysfunction

Eur Heart J. 2014 Nov 14;35(43):3021-32. doi: 10.1093/eurheartj/ehu111. Epub 2014 Mar 21.

Abstract

Aims: Cardiovascular events remain the leading cause of death in Western world. Atherosclerosis is the most common underlying complication driven by low-density lipoproteins (LDL) disturbing vascular integrity. Carbamylation of lysine residues, occurring primarily in the presence of chronic kidney disease (CKD), may affect functional properties of lipoproteins; however, its effect on endothelial function is unknown.

Methods and results: Low-density lipoprotein from healthy donors was isolated and carbamylated. Vascular reactivity after treatment with native LDL (nLDL) or carbamylated LDL (cLDL) was examined in organ chambers for isometric tension recording using aortic rings of wild-type or lectin-like-oxidized LDL receptor-1 (LOX-1) transgenic mice. Reactive oxygen species (ROS) and nitric oxide (NO) production were determined using electron spin resonance spectroscopy. The effect of LDL-carbamyl-lysine levels on cardiovascular outcomes was determined in patients with CKD during a median follow-up of 4.7 years. Carbamylated LDL impaired endothelium-dependent relaxation to acetylcholine or calcium-ionophore A23187, but not endothelium-independent relaxation to sodium nitroprusside. In contrast, nLDL had no effect. Carbamylated LDL enhanced aortic ROS production by activating NADPH-oxidase. Carbamylated LDL stimulated endothelial NO synthase (eNOS) uncoupling at least partially by promoting S-glutathionylation of eNOS. Carbamylated LDL-induced endothelial dysfunction was enhanced in LOX-1 transgenic mice. In patients with CKD, LDL-carbamyl-lysine levels were significant predictors for cardiovascular events and all-cause mortality.

Conclusions: Carbamylation of LDL induces endothelial dysfunction via LOX-1 activation and increased ROS production leading to eNOS uncoupling. This indicates a novel mechanism in the pathogenesis of atherosclerotic disease which may be pathogenic and prognostic in patients with CKD and high plasma levels of cLDL.

Keywords: Carbamylation; Endothelial function; Lipoprotein; Nitric oxide; Reactive oxygen species.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Acetylcholine / pharmacology
  • Analysis of Variance
  • Animals
  • Aorta / physiology
  • Cardiovascular Diseases / physiopathology
  • Endothelium, Vascular / physiopathology*
  • Enzyme Inhibitors / pharmacology
  • Healthy Volunteers
  • Humans
  • In Vitro Techniques
  • Lipoproteins, LDL / metabolism
  • Lipoproteins, LDL / pharmacology
  • Lipoproteins, LDL / physiology*
  • Mice, Inbred C57BL
  • Mice, Transgenic
  • Nitric Oxide Synthase Type III / metabolism
  • Onium Compounds / pharmacology
  • Reactive Oxygen Species / metabolism
  • Renal Insufficiency, Chronic / metabolism
  • Renal Insufficiency, Chronic / physiopathology
  • Scavenger Receptors, Class E / metabolism
  • Vasodilation / drug effects
  • Vasodilator Agents / pharmacology

Substances

  • Enzyme Inhibitors
  • Lipoproteins, LDL
  • Olr1 protein, mouse
  • Onium Compounds
  • Reactive Oxygen Species
  • Scavenger Receptors, Class E
  • Vasodilator Agents
  • carbamyl-LDL
  • diphenyleneiodonium
  • Nitric Oxide Synthase Type III
  • Acetylcholine